As per attachment
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GlaxoSmithKline Pharmaceuticals reported audited annual results for FY2026 ending March 31. Consolidated revenue from operations grew 1.9% to Rs. 382,167 lakhs from Rs. 374,921 lakhs. Profit after tax (PAT) rose 11.7% to Rs. 103,598 lakhs from Rs. 92,758 lakhs. Basic EPS (consolidated) increased to Rs. 61.15 from Rs. 54.76. The Board recommended a final dividend of Rs. 57 per equity share (face value Rs. 10), up from Rs. 54 last year. Exceptional items included Rs. 2,062 lakhs from sale of surplus properties. Statutory auditors Deloitte Haskins & Sells LLP issued an unmodified (clean) opinion on both standalone and consolidated financial statements. Record date for dividend is May 29, 2026, with payment after July 1, 2026 subject to shareholder approval at the June 30 AGM.
The company delivered double-digit PAT growth (~12%) on modest revenue growth (~2%), indicating margin improvement. The increased dividend and clean audit opinion signal financial stability, which should be positive for shareholders.